(142) Erythrocyte membrane biomimetic nanoparticles for Dapagliflozin delivery in the fibrotic heart

Introduction: Myocardial infarction often causes cardiac insufficiency, leading to fibrosis and heart failure (HF) [1]. Gliflozins (e.g., Dapagliflozin), used for type 2 diabetes, showed promise in reducing cardiovascular death and hospitalization for HF [2]. They can improve fibrosis post-ischemia, but the mechanisms remain unclear, and potential side effects exist [3-4]. The use nanoparticles (NPs) as in situ injectable drug delivery systems offers potential advantages. This study aimed at developing erythrocytes membrane-based biomimetic NPs as a new tool for Dapagliflozin delivery in the fibrotic heart.